Published in J Clin Invest on January 01, 1985
An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U S A (1985) 1.90
Glycosaminoglycans and the regulation of blood coagulation. Biochem J (1993) 1.57
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol (1990) 1.40
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest (1987) 1.07
Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates. Biochem J (1986) 1.07
Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J (1986) 0.95
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest (1985) 0.94
PF4/heparin complexes are T cell-dependent antigens. Blood (2005) 0.93
Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells. J Exp Med (1985) 0.91
Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa. Biochem J (1989) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Immunization, isolation of immunoglobulins, estimation of antibody titre. Scand J Immunol Suppl (1973) 6.38
Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood (1978) 5.18
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes. Biochemistry (1969) 2.61
Anticoagulant action of heparin. Nature (1973) 2.26
Proteolytic activation of protein C from bovine plasma. Biochemistry (1976) 2.12
Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry (1973) 2.04
Prothrombin. Methods Enzymol (1976) 1.89
Bovine factors X 1 and X 2 (Stuart factor). Isolation and characterization. Biochemistry (1972) 1.73
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J Biol Chem (1983) 1.55
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Preparation and partial characterization of two forms of bovine thrombin. Biochem Biophys Res Commun (1975) 1.48
Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH). Thromb Res (1977) 1.46
Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. J Biol Chem (1980) 1.42
Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem (1973) 1.39
Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem (1979) 1.36
Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry (1976) 1.35
Microvascular heparin-like species with anticoagulant activity. Am J Physiol (1983) 1.34
Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem (1982) 1.25
Inhibition of human factor IXa by human antithrombin. J Biol Chem (1975) 1.25
Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest (1982) 1.16
Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry (1976) 1.16
Formation and dissociation of the covalent complexes between trypsin and two homologous inhibitors, alpha 1-antitrypsin and antithrombin III. Eur J Biochem (1980) 1.10
Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diath Haemorrh (1974) 1.10
Activation of factor IX bound to cultured bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1984) 1.08
The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem (1982) 1.03
Antibodies to the heparan sulfate proteoglycans synthesized by endothelial cell cultures. Biochim Biophys Acta (1983) 1.01
Biological properties of the naturally occurring plasma inhibitor to activated factor X. J Biol Chem (1971) 0.99
Anti-clotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochem Biophys Res Commun (1982) 0.98
The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem (1980) 0.92
Factor IX antigen by a rapid staphylococcal protein A-membrane binding radioimmunoassay: results in haemophilia B patients and carriers and in fetal samples. Br J Haematol (1982) 0.92
Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood (1983) 0.91
Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemost (1980) 0.88
Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation. J Biol Chem (1984) 0.87
Familial functional antithrombin III deficiency. Scand J Haematol (1980) 0.86
A simple amidolytic method for the determination of functional active antithrombin III. Scand J Clin Lab Invest (1976) 0.85
A new familial variant of antithrombin III: 'antithrombin III Paris'. Br J Haematol (1982) 0.85
Radioimmunoassay of platelet factor 4. Methods Enzymol (1982) 0.80
Inactivation of bovine and human thrombin and factor Xa by antithrombin III studied with amidolytic methods. Thromb Res (1977) 0.79
Transformation of active-site lysine in naturally occurring trypsin inhibitors. A basis for a general mechanism for inhibition of proteolytic enzymes. Biochemistry (1968) 0.79
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
The Berkeley Drosophila Genome Project gene disruption project: Single P-element insertions mutating 25% of vital Drosophila genes. Genetics (1999) 7.56
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
The coagulation cascade: initiation, maintenance, and regulation. Biochemistry (1991) 6.29
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med (1986) 5.17
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol (1981) 3.41
Self-regulation of procoagulant events on the endothelial cell surface. J Exp Med (1985) 3.16
Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis (2001) 3.06
Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry (1977) 2.96
RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 2.96
Regulation of acetylcholinesterase in neuroblastoma cells. Proc Natl Acad Sci U S A (1970) 2.89
The mosquito Anopheles stephensi limits malaria parasite development with inducible synthesis of nitric oxide. Proc Natl Acad Sci U S A (1998) 2.83
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 2.59
Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med (1989) 2.52
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest (2001) 2.45
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med (2000) 2.44
An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 2.42
Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res (1980) 2.40
Context, conflict, and resolution: a new conceptual framework for evaluating professionalism. Acad Med (2000) 2.39
The role of serine proteases in the blood coagulation cascade. Adv Enzymol Relat Areas Mol Biol (1979) 2.21
Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A (1990) 2.18
Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest (1979) 2.18
Proteolytic activation of protein C from bovine plasma. Biochemistry (1976) 2.12
Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med (2000) 2.09
Management of heparin therapy: Controlled prospective trial. N Engl J Med (1975) 2.07
Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol (1993) 2.07
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb (1994) 2.05
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest (1996) 2.03
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest (1993) 1.99
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A (1994) 1.91
An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U S A (1985) 1.90
Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A (1986) 1.89
A study of lower-limb mechanics during stair-climbing. J Bone Joint Surg Am (1980) 1.89
High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol (1995) 1.87
Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest (1990) 1.84
Cellular requirements for tissue factor generation by bovine aortic endothelial cells in culture. Thromb Res (1985) 1.83
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.82
Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis (2000) 1.73
Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med (1988) 1.71
Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost (1996) 1.71
Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med (1995) 1.69
Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol (1986) 1.68
Risk factors associated with human cystic echinococcosis in Florida, Uruguay: results of a mass screening study using ultrasound and serology. Am J Trop Med Hyg (1998) 1.68
Development and evaluation of an enzyme-linked immunosorbent assay for Plasmodium vivax-VK247 sporozoites. J Med Entomol (1992) 1.64
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol (1994) 1.62
Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J Clin Invest (1982) 1.60
Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem (1995) 1.58
Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A (1998) 1.57
Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int (2006) 1.53
Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest (1998) 1.51
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med (2000) 1.50
Identification of Plasmodium vivax sporozoites in mosquitoes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg (1985) 1.50
Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol (2000) 1.50
Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc Natl Acad Sci U S A (1997) 1.49
Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest (1997) 1.49
Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid. Biochemistry (1983) 1.47
Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst (2000) 1.44
Evidence that an Arg79-->Gln substitution in human factor VII is not associated with a reduction in coagulant activity. Blood Coagul Fibrinolysis (1992) 1.43
Management of hypertension in twelve Oxfordshire general practices. J R Coll Gen Pract (1986) 1.43
The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand (1981) 1.43
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology (2004) 1.42
Naive neutrophils and xenotransplantation. Lancet (1996) 1.41
Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest (2001) 1.40
beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol (2000) 1.40
Inability of Plasmodium knowlesi sporozoites to invade Anopheles freeborni salivary glands. Am J Trop Med Hyg (1985) 1.38
Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A (1994) 1.38
The Treatment, Pathology and Prevention of Mental Disorders in the Aged. Can Med Assoc J (1942) 1.38
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med (1995) 1.37
Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology (1996) 1.36
Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem (1979) 1.36
Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci U S A (1984) 1.36
Forest malaria in Bangladesh. II. Transmission by Anopheles dirus. Am J Trop Med Hyg (1982) 1.35
Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry (1976) 1.35
Interaction of vitamin K dependent proteins with membranes. Biochemistry (1978) 1.35
Transcriptional and post-transcriptional control of plastid mRNA levels in higher plants. Trends Genet (1988) 1.34
RAGE: a novel cellular receptor for advanced glycation end products. Diabetes (1996) 1.34
Taxol produces a predominantly sensory neuropathy. Neurology (1989) 1.32